In this CMEO BriefCase, entitled Recognizing IH: The Patient Diagnostic Journey, expert faculty will walk through a case-driven discussion on the significant impact of symptoms on QoL and work/psychosocial functioning for patients with IH, and how this leads to delays in screening and diagnosis.
Paul P. Doghramji, MD, FAAFP, is a Senior Family Physician with Collegeville Family Practice and Medical Director of Health Services for Ursinus College in Collegeville, Pennsylvania. Dr. Doghramji earned his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania and completed residency in Family Practice at Chestnut Hill Hospital. He is a member of the American Academy of Family Physicians (AAFP) and was awarded the AAFP Fellowship Degree in 2005. He is a member of the Pennsylvania Academy of Family Physicians. Dr. Doghramji has been the recipient of the American Medical Association’s Physician Recognition Award in every qualifying year for 8 years. He has extensively published his research in peer-reviewed journals such as the American Journal of Medicine, Current Medical Research and Opinion, and Postgraduate Medicine. He has authored articles for numerous websites on topics such as sleep disorders, gout, rheumatoid arthritis (RA), biology of leg disorders, depression, chronic pain, health literacy, and diabetes. He is a co-author of the textbook Clinical Management of Insomnia, now in its second edition.
Dr. Thorpy is a Professor of Neurology at Albert Einstein College of Medicine and Director of the Sleep-Wake Disorders Center in the Department of Neurology at Montefiore Medical Center, both in New York. In addition to treating patients with sleep disorders, he conducts research in narcolepsy, insomnia, and sleep apnea. He is President of the New York State Society of Sleep Medicine, Past President of the Sleep Section of the Academy of Neurology, and Past Secretary of the National Sleep Foundation. In 1993 Dr. Thorpy received the Nathaniel Kleitman Award from the American Academy of Sleep Medicine, one of the field’s highest honors, and in 2012 he received the Lifetime Achievement Award from the National Sleep Foundation.
Born in New Zealand, Dr. Thorpy earned his medical degree from the University of Otago Medical School. After receiving postgraduate training in Dunedin, New Zealand; Bombay, India; and London, England, he completed his residency in neurology at the State University of New York in Syracuse and a neuroendocrinology fellowship at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Thorpy is board certified in sleep medicine.
He has published extensively on narcolepsy, insomnia, and sleep disorders. He chaired the first International Classification of Sleep Disorders and has published more than 250 peer-reviewed articles and chapters, including publications in journals such as The New England Journal of Medicine. His numerous books include The Encyclopedia of Sleep and Sleep Disorders, Parasomnias (2010), Sleepiness (2011), Neuroimaging of Sleep and Sleep Disorders (2012), Genetics of Sleep and Sleep Disorders (2013), Narcolepsy: a Clinical Guide (2016), and SleepMultiMedia, The Computerized Textbook of Sleep Medicine (v12).0 (2023).
Dr. Thorpy has given more than 100 television, radio, and print interviews on sleep disorders.
This educational webcast titled, Evaluation, Treatment, and Non-Stigmatizing Care for Adolescents with Obesity, will feature expert faculty leading a conversation on how to achieve an equitable, universal approach to treating patients with obesity in the pediatric setting. The discussion will provide learners with a plan to evaluate patients, consider their social determinants of health, initiate appropriate therapies, and monitor treatment. Strategies to implement shared decision-making and other empathetic communications will encourage long-term patient engagement.
Dr. Angie Golden is a current fellow and past president of the American Association of Nurse Practitioners (AANP). She owns NP Obesity Treatment Clinic in Flagstaff, AZ, where she provides evidence-based obesity treatment. She earned the Obesity Medical Association (OMA) NP/PA Certificate of Advanced Clinical Education and the Specialist Certification of Obesity Professional Education, an internationally recognized certification.
Dr. Golden has a great deal of experience as a consultant in the development of patient education materials; authored a book, Treating Obesity in Primary Care, and several book chapters on obesity management; written several peer-reviewed articles and participated in research; and been interviewed by lay media on obesity treatment. She presents nationally and internationally with an emphasis on obesity, health policy, leadership, and clinical care.
Dr. Stanford is an Associate Professor of Medicine and Pediatrics who practices and teaches at Massachusetts General Hospital (MGH)/ Harvard Medical School (HMS) as one of the first fellowship-trained obesity medicine physicians worldwide. She is among the most highly cited obesity medicine physician-scientists with over 170 peer-reviewed publications. Dr. Stanford received her BS and MPH from Emory University as an MLK Scholar, her MD from the Medical College of Georgia School of Medicine as a Stoney Scholar, her MPA from the Harvard Kennedy School of Government as a Zuckerman Fellow in the Harvard Center for Public Leadership and her executive MBA as a merit-based scholarship recipient from the Quantic School of Business and Technology. She completed her Obesity Medicine & Nutrition Fellowship at MGH/HMS after completing her internal medicine and pediatrics residency at the University of South Carolina. She has served as a health communications fellow at the Centers for Disease Control and Prevention and as a behavioral sciences intern at the American Cancer Society. Upon completing her MPH, she received the Gold Congressional Award, the highest honor Congress bestows upon America’s youth.
Dr. Stanford has completed a medicine and media internship at the Discovery Channel. An American Medical Association (AMA) Foundation Leadership Award recipient in 2005 and an AMA Paul Ambrose Award for national leadership among resident physicians in 2009, she was selected for the AMA Inspirational Physician Award in 2015. The American College of Physicians (ACP) selected her as the 2013 Joseph E. Johnson Leadership Award recipient, and the Massachusetts ACP selected her for the Young Leadership Award in 2015. She is the 2017 recipient of the HMS Amos Diversity Award and the Massachusetts Medical Society (MMS) Award for Women’s Health. In 2019, she was selected as the Suffolk District Community Clinician of the Year for the Reducing Health Disparities Award for MMS. She was chosen for The Obesity Society Clinician of the Year in 2020. In 2021, she was awarded the MMS Grant Rodkey Award for her dedication to medical students and the AMA Dr. Edmond and Rima Cabbabe Dedication to the Profession Award, which recognizes a physician who demonstrates active and productive improvement to the profession of medicine through community service, advocacy, leadership, teaching, or philanthropy. She is the 2021 Recipient of the Emory Rollins School of Public Health Distinguished Alumni Award. In 2022, the National Academy of Medicine selected her as a Scholar in Diagnostic Excellence. She was named to the 2025 Dietary Guidelines Advisory Committee by the US Department of Health and Human Services (HHS) and Agriculture (USDA).
In this recorded CME Outfitters webcast entitled, Tricky Business: Rethinking Our Approach to Tackling Schizophrenia, a panel of expert faculty will utilize animated 3-D models to discuss pathophysiology, negative symptomology, and CIAS in schizophrenia, identify the impact of unmet patient medical needs and examine current emerging therapies in the treatment of schizophrenia.
Rakesh Jain, MD, MPH, is a Clinical Professor in the department of Psychiatry at the Texas Tech Health Sciences Center School of Medicine – Permian Basin in Midland, Texas and in private practice in Austin, Texas. Dr. Jain attended medical school at the University of Calcutta in India. He received his Master of Public Health (MPH) degree from the University of Texas School of Public Health in Houston, where he was awarded a National Institute/Center for Disease Control Competitive Traineeship. His research thesis focused on the impact of substance abuse.
Dr. Jain completed his residency in psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston. He then completed a postdoctoral fellowship in research psychiatry at the University of Texas Mental Sciences Institute in Houston. He was awarded the National Research Service Award in support of his postdoctoral fellowship.
Dr. Jain has been involved in over 100 research projects studying the effects of medications on short-term and long-term treatment of depression, anxiety, pain/mood overlap disorders, ADHD, and psychosis in adult and child/adolescent populations. He has presented at the World Psychiatric Congress held in Prague, and at Depression and Pain Forum meetings internationally. He is the author of 55 articles published in various journals and magazines, such as the Journal of Psychiatric Research and Journal of Clinical Psychiatry, among others, and has presented over 25 original research posters at meetings such as the American Psychological Association (APA), the American College of Neuropsychopharmacology (ACNP), the American Academy of Child and Adolescent Psychiatry (AACAP), the U.S. Psychiatric Congress, and more. He has co-authored six books that range from patient education to cutting-edge neurobiologic findings in psychiatry and mental health. He serves on several advisory boards focusing on drug development and disease state education. He was also recently the Chair of the U.S. Psychiatric Congress, and for several years, has served as a member of the Steering Committee for U.S. Psychiatric Annual Congress. He is a recipient of the Public Citizen of the Year award from the National Association of Social Workers, Gulf Coast Chapter, in recognition of his community and peer education, and championing of mental health issues.
Dr. Dawn Velligan is a Professor in the Department of Psychiatry, Chief of the Division of Community Recovery, Research and Training, and Henry B. Dielmann Chair at the University of Texas Health Science Center at San Antonio. Dr. Velligan’s internationally recognized research program focuses on the development and testing of psychosocial treatments to bypass cognitive and motivation problems in schizophrenia and improve medication follow through and outcomes. She developed Cognitive Adaptation Training (CAT) a unique treatment system designed to bypass the cognitive problems observed in serious mental illness and improve functional outcomes. Dr. Velligan has dedicated her career to developing, and delivering state-of-the-art psychosocial treatments to make lives better for those with serious mental illness. Dr. Velligan’s latest work has included the development of a multi-level program targeting administrators, providers, and individuals in treatment to facilitate shared decision making and increase the use of long-acting formulations of antipsychotic medication at the systems level. Dr. Velligan is author of numerous publications in high impact journals on cognitive and functional impairment and adherence and she has received grant funding from the National Institute of Health, The Brain and Behavior Research Foundation, industry and private foundations. She frequently serves as a consultant to industry and scientific investigators in the areas of symptom assessment, medication adherence and follow through, cognition and outcomes.
Christoph U. Correll is a Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, and serves as Professor and Chair of the Department of Child and Adolescent Psychiatry, at Charité University Medicine, Berlin, Germany. Dr. Correll completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed two residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, and since 2017 he has been working in Germany.
Dr. Correll focuses on the identification and treatment of youth and adults with severe mental illness, clinical trials, epidemiology, psychopharmacology, meta-analyses, and the interface between physical health and mental health. He has authored or co-authored over 850 journal articles that have been cited more than 68.000 times and received over 40 research awards for his work. In August 2023, his H-index was 136 in Google Scholar. Since 2014, the beginning of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry” (https://hcr.clarivate.com).
This 60-minute program will explore real-world applications of the data to practice, with a diverse panel offering unique perspectives on the genetic testing landscape in NICU settings.
Wendy Chung, MD, PhD, a clinical and molecular geneticist, is the Chief of the Department of Pediatrics at Boston Children’s Hospital and the Mary Ellen Avery Professor at Harvard Medical School. She received her bachelor’s degree in biochemistry from Cornell University, her medical degree from Cornell University Medical College, and her doctorate in genetics from The Rockefeller University.
Dr. Chung directs National Institutes of Health (NIH)-funded research programs in human genetics of pulmonary hypertension, breast cancer, obesity, diabetes, autism, birth defects—including congenital diaphragmatic hernia—and congenital heart disease. She is a leader in the ethical, legal, and social implications of genomics, and leads the National Organization of Rare Disorders Center of Excellence at Columbia University. She is a recipient of the New York Academy of Medicine Medal for Distinguished Contributions in Biomedical Science and the Rare Impact Award from the National Organization of Rare Disorders, and is a member of the National Academy of Medicine and the American Academy of Physicians.
Rebecca Burke, MD, PhD, is an assistant professor of pediatrics within the divisions of neonatal-perinatal medicine and medical genetics at Penn State Health Milton S. Hershey School of Medicine. She received her medical and graduate degrees from the University of Arkansas for Medical Sciences in Little Rock, AK. She completed her medical residency in general pediatrics at Thomas Jefferson University/ Nemours Children’s Hospital née AI duPont Hospital for Children in Wilmington, DE, where she realized her calling in medicine was to care for fragile neonates and children with rare genetic disorders. She then completed a combined neonatology and clinical genetics fellowship at Texas Children’s Hospital-Baylor College of Medicine in Houston, TX.
Dr. Burke is a passionate advocate for children with complex medical conditions and their families. In addition to her neonatology and genetics practices, she participates in undergraduate and graduate medical education with a goal to increase genetic literacy and awareness among all medical specialties. Her clinical interests include exome and genome sequencing in newborns, and prenatal consultation for families with pregnancies complicated by fetal anomalies.
Michelle Fergus is a professional, a sister, a fiancé, and a mom to 3-year-old Michael, who has a rare genetic disorder called hereditary fructose intolerance (HFI). Michelle and her partner, Mick, found themselves in a true S.O.S. situation when their son was hospitalized at 3-months old. His first week in the hospital provided no answers, and the second week produced only guesses, until a doctor suggested genetic testing. If their son had not undergone testing, he would not be with them today—genetic testing saved his life. Since then, they have been educating themselves on everything associated with HFI.
This initiative seeks to fill those knowledge gaps among cardiologists and clinicians caring for patients with cancer who receive ICI therapy. Clinicians will receive education on the available clinical evidence to make informed decisions regarding resumption of therapy.
Dr. Neilan received his MD from University College Dublin and MPH from Harvard School of Public Health. He completed internal medicine residency and cardiology training at the Mater Misericordiae Hospital in Dublin and again at Massachusetts General Hospital. He has also completed extensive training in echocardiography at Massachusetts General Hospital and in cardiac magnetic resonance at the Brigham and Women’s Hospital. Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program, and the Co-Director of the Cardiac MR PET CT Program.
Dr. Neilan has had a long-standing clinical and research interest in the cardiovascular care of patients with cancer. Cardiovascular disease is a leading cause of death and disability among cancer survivors and cardiovascular care for patients with cancer requires a tailored approach that is unique for each patient. He is specifically interested in how we can improve on the methods for detection of cardiac toxicity after chemotherapy and radiotherapy and to use that information to determine how we care for patients.
Dr. Kerry Reynolds is an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications (SIC) Service and the Clinical Director for Inpatient Cancer Services at Mass General Cancer Center. She joined the Harvard Medical School faculty in 2014, after completing her residency and chief residency at Massachusetts General and fellowship training in Oncology at Dana-Farber/Partners Cancer Care.
The SIC Service is the first program of its kind in the country. Every hospitalized patient at Mass General Cancer Center who has received immunotherapy and is suspected to be experiencing an immune-related adverse event (irAE) is seen by one of the Service’s dedicated oncologists, resulting in unparalleled care for this type of toxicity. Under the leadership of Dr. Reynolds, the SIC Service now provides care to a significant number of patients every year and has grown to comprise more than 50 clinicians and researchers across 19 different areas of the hospital, including subspecialists from oncology, cardiology, dermatology, gastroenterology, and many more relevant disciplines.
In addition to providing clinical care, supervising and educating trainees, and participating in administrative affairs, Dr. Reynolds leverages the work of the SIC Service to conduct research on the severe toxicities associated with immunotherapy. Her ultimate goal is to improve the lives of patients undergoing immunotherapy by uncovering irAE predictors and biomarkers, characterizing the clinical presentations of irAEs, developing best practices for managing irAEs, and elucidating the mechanisms that drive irAEs in order to develop novel therapies. To pursue this goal, she is working with Dr. Alexandra-Chloe Villani to systematically collect blood and tissue samples from patients with irAEs and analyze them using cutting-edge technologies. Dr. Reynolds has also authored numerous peer-reviewed publications and several book chapters, and she was lead editor of Facing Immunotherapy: A Guide for Patients and Their Families.
In this CME Outfitters BriefCase, expert faculty will guide learners through a case involving a patient who presents with escalating symptoms of an irAE over multiple visits.
Jordan McPherson, PharmD, MS, BCOP, is an Oncology Clinical Pharmacist in the outpatient solid tumor clinics at Huntsman Cancer Institute, an NCI-designated cancer hospital on the campus of the University of Utah Health in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of melanoma and non-melanoma skin cancers using immunotherapy and other targeted therapies. He serves as a panel member on the National Comprehensive Cancer Network Guidelines for the Management of Immunotherapy-Related Toxicities, and as Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson is passionate about pharmacist involvement in the recognition and management of immune-related adverse events in both oncology and non-oncology settings. Dr. McPherson’s research efforts are well published in peer-reviewed journals, including the Journal for ImmunoTherapy of Cancer (JITC), Pharmacotherapy, JCO Clinical Cancer Informatics, Cancer Chemotherapy and Pharmacology, and Haemophilia.
Dr. Kerry Reynolds is an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications (SIC) Service and the Clinical Director for Inpatient Cancer Services at Mass General Cancer Center. She joined the Harvard Medical School faculty in 2014, after completing her residency and chief residency at Massachusetts General and fellowship training in Oncology at Dana-Farber/Partners Cancer Care.
The SIC Service is the first program of its kind in the country. Every hospitalized patient at Mass General Cancer Center who has received immunotherapy and is suspected to be experiencing an immune-related adverse event (irAE) is seen by one of the Service’s dedicated oncologists, resulting in unparalleled care for this type of toxicity. Under the leadership of Dr. Reynolds, the SIC Service now provides care to a significant number of patients every year and has grown to comprise more than 50 clinicians and researchers across 19 different areas of the hospital, including subspecialists from oncology, cardiology, dermatology, gastroenterology, and many more relevant disciplines.
In addition to providing clinical care, supervising and educating trainees, and participating in administrative affairs, Dr. Reynolds leverages the work of the SIC Service to conduct research on the severe toxicities associated with immunotherapy. Her ultimate goal is to improve the lives of patients undergoing immunotherapy by uncovering irAE predictors and biomarkers, characterizing the clinical presentations of irAEs, developing best practices for managing irAEs, and elucidating the mechanisms that drive irAEs in order to develop novel therapies. To pursue this goal, she is working with Dr. Alexandra-Chloe Villani to systematically collect blood and tissue samples from patients with irAEs and analyze them using cutting-edge technologies. Dr. Reynolds has also authored numerous peer-reviewed publications and several book chapters, and she was lead editor of Facing Immunotherapy: A Guide for Patients and Their Families.